Company

Ymmunobio

Biotechnology Research Basel, Basel-stadt, Ch 6 employees

Employees: 6
Contacts: 3
Emails: 3
Phones: 1

www.ymmuno.bio LinkedIn

Ymmunobio Overview

Headquarters: Basel, Basel-stadt, Ch
Website: www.ymmuno.bio
Industry: Biotechnology Research
Employees: 6
Founded: 2021
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

NXI Therapeutics AG

About Ymmunobio

Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have unique features of fighting cancers.

Ymmunobio Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Ymmunobio Org Chart

Sample employees and titles

Name	Title	Location	Contact
Christian Germa	Non Executive Director	Short Hills, New Jersey, United States	Email
Michel Janicot	Founder & Managing Director at Jmi Onconsulting	Ukkel, Brussels Region, Belgium	Email
Martin E. Zuzulo	Managing Director-americas, Widler & Schiemann, Llc	Greater Philadelphia, United States	Email Phone
Juergen Heitmann	Business Development Executive		View